HanchorBio is a biotechnology company focused on immuno-oncology that develops proprietary Fc-based designer biologics (FBDB™) with multi-targeting modalities. Founded in December 2020, the company operates out of Taipei, Shanghai, and San Francisco and is led by industry veterans experienced in biologics discovery and global development. Its FBDB™ platform aims to reactivate innate and adaptive immune systems to kill tumors through multifunctional molecular configurations. HanchorBio reported promising in-vivo data from multiple tumor animal models across several projects. The company intends to use new financing to advance its growing pipeline, support IND-enabling GLP toxicology studies and IND submissions, and fund the first part of Phase 1 clinical trials. Management emphasizes improvements in R&D methodologies and CMC process development to translate novel biologics into transformative therapies.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2022